NBIX

NBIX

USD

Neurocrine Biosciences Inc. Common Stock

$143.190+1.220 (0.859%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$141.970

高値

$143.870

安値

$140.820

出来高

0.26M

企業ファンダメンタルズ

時価総額

14.3B

業種

Drug Manufacturers - Specialty & Generic

United States

取引統計

平均出来高

0.86M

取引所

NMS

通貨

USD

52週レンジ

安値 $84.23現在値 $143.190高値 $154.61

関連ニュース

Analyst Upgrades

Truist Securities Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $172

Truist Securities analyst Danielle Brill reiterates Neurocrine Biosciences with a Buy and raises the price target from $165 to $172.

もっと見る
Truist Securities Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $172
Analyst Upgrades

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences with a Buy and raises the price target from $160 to $164.

もっと見る
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164
Analyst Upgrades

Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $183

Stifel analyst Paul Matteis maintains Neurocrine Biosciences with a Buy and raises the price target from $174 to $183.

もっと見る
Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $183
Analyst Upgrades

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $160

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences with a Outperform and raises the price target from $156 to $160.

もっと見る
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $160
Analyst Upgrades

Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $179

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences with a Overweight and raises the price target from $175 to $179.

もっと見る
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $179
Analyst Upgrades

Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $184

Needham analyst Ami Fadia maintains Neurocrine Biosciences with a Buy and raises the price target from $170 to $184.

Analyst Upgrades

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $195

UBS analyst Ashwani Verma maintains Neurocrine Biosciences with a Buy and raises the price target from $188 to $195.